A Budget Impact Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS) In The UK

October 18, 2018 Danielle Twigg

Cladribine Tablets (MAVENCLAD®) received its marketing authorization from the European Medicines Agency (EMA) for the treatment of persons with Highly Active Relapsing Multiple Sclerosis (HA-RMS) in 2017. Since then, in the United Kingdom (U.K.), it was assessed by the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium, where it has received positive approval for use in the National Health Service (NHS). The aim of this analysis was to assess the budget impact of Cladribine Tablets against other HA-RMS Disease Modifying Treatments (DMTs), such as alemtuzumab, fingolimod, and natalizumab in a UK setting.

Authors: Harty G, Treharne C, Budhia S, Wong SL

To find out more about this poster you can register to download it here after the ISPOR event.

Previous Article
A Cost Minimisation Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS)
A Cost Minimisation Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS)

Next Article
Are Nice And The SMC Diverging In Their Assessment Of Oncology Drugs?
Are Nice And The SMC Diverging In Their Assessment Of Oncology Drugs?